In the year to date, Hikma's Injectables business has delivered strong organic growth across the US, Europe and the MENA region. This performance has been driven by new product launches, increased tender sales, better portfolio management, new contract wins, more efficient manufacturing and increased demand from continuing product shortages in the US. In August, Hikma announced a 94% increase in revenues to $225.2 million and adjusted EBIT margin of 22.0% for the six months ended 30 June 2012. At this time, the company stated that the first half performance was expected to be sustained in the second half of the year. Hikma reiterates this view and continues to see strong potential for its global Injectables business in the coming years.

Said Darwazah, Chief Executive Officer of Hikma, said: "We are delighted with the performance of our global Injectables business, which has been transformed by the acquisition of MSI. Our track record of investing in our high-quality manufacturing facilities and product portfolio is helping to drive the excellent growth seen so far this year and we remain very optimistic about the prospects for our global Injectables business both in the short and longer term."

A live webcast and presentation slides will be available at 9am EST / 2pm GMT on Hikma’s website. Please follow this link to view the event:http://www.hikma.com/en/investors/analyst-investor-day.aspx